Reactive uveitis, retinal vasculitis and scleritis as ocular end-stage of Acanthamoeba keratitis: a histological study.

We analysed histologically two Acanthamoeba keratitis (AK) eyes with anterior and posterior segment inflammation and blindness. Two enucleated eyes of 2 patients (age 45 and 51y) with AK (PCR of epithelial abrasion positive) were analysed. Histological analysis was performed using hematoxylin-eosin, periodic acid-Schiff and Gömöri-methenamine silver staining. We could not observe Acanthamoeba trophozoites or cysts neither in the cornea nor in other ocular tissues. Meanwhile, we found uveitis, retinal vasculitis and scleritis in these eyes, due to the long-standing, recalcitrant AK. So in this stage of AK, systemic immune suppression may be necessary for a longer time period.

[1]  B. Seitz,et al.  Early Penetrating Keratoplasty À Chaud May Improve Outcome in Therapy-Resistant Acanthamoeba Keratitis , 2019, Advances in Therapy.

[2]  R. Rammohan,et al.  The Acanthamoeba-Fungal Keratitis Study. , 2019, American journal of ophthalmology.

[3]  B. Seitz,et al.  The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, In Vitro , 2018, Current eye research.

[4]  R. Dana,et al.  Kinetics of Corneal Antigen Presenting Cells in Experimental Dry Eye Disease , 2017, BMJ Open Ophthalmology.

[5]  J. Niederkorn,et al.  Pathobiology and Immunobiology of Acanthamoeba Keratitis: Insights from Animal Models
 , 2017, The Yale journal of biology and medicine.

[6]  Julia F. Reverey,et al.  Adhesion forces and mechanics in mannose-mediated acanthamoeba interactions , 2017, PloS one.

[7]  N. Bechrakis,et al.  Severe reactive ischemic posterior segment inflammation in Acanthamoeba keratitis , 2017, Spektrum der Augenheilkunde.

[8]  V. Mahajan,et al.  ACANTHAMOEBA ENDOPHTHALMITIS AFTER RECURRENT KERATITIS AND NODULAR SCLERITIS , 2017, Retinal cases & brief reports.

[9]  A. Fuentefria,et al.  Acanthamoeba and Fusarium interactions: A possible problem in keratitis. , 2016, Acta tropica.

[10]  V. Jhanji,et al.  Acanthamoeba keratitis: 10-year study at a tertiary eye care center in Hong Kong. , 2015, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[11]  N. Panjwani,et al.  IL-17A–Mediated Protection against Acanthamoeba Keratitis , 2014, The Journal of Immunology.

[12]  Brian D. Poole,et al.  B cell epitope spreading: mechanisms and contribution to autoimmune diseases. , 2015, Immunology letters.

[13]  A. Iovieno,et al.  Acanthamoeba sclerokeratitis: epidemiology, clinical features, and treatment outcomes. , 2014, Ophthalmology.

[14]  K. Wilhelmus,et al.  Rapidly progressive cataract and iris atrophy during treatment of Acanthamoeba keratitis. , 2006, Ophthalmology.

[15]  J. Niederkorn,et al.  Effect of immunization with the mannose-induced Acanthamoeba protein and Acanthamoeba plasminogen activator in mitigating Acanthamoeba keratitis. , 2007, Investigative ophthalmology & visual science.

[16]  W. Petroll,et al.  Severe reactive ischemic posterior segment inflammation in acanthamoeba keratitis: a new potentially blinding syndrome. , 2007, Ophthalmology.

[17]  H. D. Cavanagh,et al.  Updates in Acanthamoeba Keratitis , 2007, Eye & contact lens.

[18]  R. Dana,et al.  Corneal antigen-presenting cells. , 2007, Chemical immunology and allergy.

[19]  J. Niederkorn,et al.  Failure of Acanthamoeba castellanii to produce intraocular infections. , 2005, Investigative ophthalmology & visual science.

[20]  G. Sutton,et al.  Six‐year review of Acanthamoeba keratitis in New South Wales, Australia: 1997–2002 , 2005, Clinical & experimental ophthalmology.

[21]  W. Mathers.  Acanthamoeba: a difficult pathogen to evaluate and treat. , 2004, Cornea.

[22]  N. Ehlers,et al.  Are cataract and iris atrophy toxic complications of medical treatment of acanthamoeba keratitis? , 2004, Acta ophthalmologica Scandinavica.

[23]  J. Niederkorn,et al.  Pathogenic Acanthamoeba spp. Secrete a Mannose-Induced Cytolytic Protein That Correlates with the Ability To Cause Disease , 2003, Infection and Immunity.

[24]  E. Mayhew,et al.  Adaptive immune responses to Acanthamoeba cysts. , 2002, Experimental eye research.

[25]  L. Ficker,et al.  Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression. , 2002, Ophthalmology.

[26]  D C Minassian,et al.  Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors , 2002, The British journal of ophthalmology.

[27]  I. McLean,et al.  Chorioretinitis after keratitis caused by Acanthamoeba: case report and review of the literature. , 2001, Ophthalmology.

[28]  H. D. Cavanagh,et al.  Tear IgA and Serum IgG Antibodies Against Acanthamoeba in Patients With Acanthamoeba Keratitis , 2001, Cornea.

[29]  H Alizadeh,et al.  The pathogenesis of Acanthamoeba keratitis. , 1999, Microbes and infection.

[30]  J. McCulley,et al.  The immunobiology of Acanthamoeba keratitis. , 1999, Springer seminars in immunopathology.

[31]  A. Reboli,et al.  Acanthamoeba endophthalmitis in acquired immunodeficiency syndrome. , 1996, American journal of ophthalmology.

[32]  J. P. Burke,et al.  Acanthamoeba polyphaga panophthalmitis. , 1992, Cornea.

[33]  G. Visvesvara,et al.  The epidemiology of Acanthamoeba keratitis in the United States. , 1989, American journal of ophthalmology.

[34]  S. Feman,et al.  Chorioretinitis in the contralateral eye of a patient with Acanthamoeba keratitis. , 1988, Ophthalmology.

[35]  G. Visvesvara,et al.  Acanthamoeba polyphaga keratitis and Acenthamoeba uveitis associated with fatal meningoencephalitis. , 1975, Transactions of the ophthalmological societies of the United Kingdom.